Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group
- 23.05.2024
- Original Research Article
Erschienen in:
- Verfasst von
- Mercedes Salgado Fernández
- Margarita Reboredo López
- Marta Covela Rúa
- Sonia Candamio
- Paula González-Villarroel
- Luis Felipe Sánchez-Cousido
- Begoña Graña
- Alberto Carral-Maseda
- Soledad Cameselle-García
- Vanesa Varela Pose
- Maria Elena Gallardo-Martín
- Nieves Martínez-Lago
- the Galician Group of Research in Digestive Tumors (GITuD)
- Erschienen in
- Targeted Oncology | Ausgabe 4/2024
Abstract
Background
There are few third- and fourth-line therapeutic options for metastatic colorectal cancer (mCRC). In RAS/BRAF wild-type (wt) mCRC previously treated with anti-epidermal growth factor receptor (anti-EGFR) (first-line) and relapsed after a good response, retreatment with anti-EGFR (rechallenge) emerges as a therapeutic alternative.
Objective
The aim was to show the activity and safety of anti-EGFR rechallenge in RAS/BRAF wt mCRC in real-world practice.
Patients and Methods
A multicenter, retrospective, observational study (six hospitals of the Galician Group of Research in Digestive Tumors) was conducted. Adult patients with RAS/BRAF wt mCRC, evaluated by liquid biopsy, were included. They received anti-EGFR rechallenge (cetuximab, panitumumab) as monotherapy, or combined with chemotherapy, in third- or subsequent lines. Efficacy (overall response rate [ORR], disease control rate [DCR], overall survival [OS], and progression-free survival [PFS]) and safety (incidence of adverse events [AEs]) were assessed.
Results
Thirty-one patients were analyzed. Rechallenge (median 6 cycles [range 1–27], mainly cetuximab [80.7%]), started at a median anti-EGFR-free time of 18.4 months (1.7–37.5 months) after two (38.7%) or more (61.3%) lines of treatment; 64.5% of patients received a full dose. Median OS and PFS were 9.8 months (95% confidence interval [CI] 8.2–11.4) and 2.6 months (95% CI 1.7–3.4), respectively. ORR was 10%, and DCR was 30%. The most common AEs were diarrhea (35.5%), anemia (29%), emesis (6.4%), and neutropenia (6.4%); < 5% grade ≥ 3; 48.4% of patients reported anti-EGFR-related skin toxicity (grade > 1). Hypomagnesemia required supplements in 29% of patients. Dose delays (≥ 3 days) and reduction (≥ 20%) were reported in 11 (35.5%) and seven patients (22.6%), respectively.
Conclusions
In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.
Anzeige
- Titel
- Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group
- Verfasst von
-
Mercedes Salgado Fernández
Margarita Reboredo López
Marta Covela Rúa
Sonia Candamio
Paula González-Villarroel
Luis Felipe Sánchez-Cousido
Begoña Graña
Alberto Carral-Maseda
Soledad Cameselle-García
Vanesa Varela Pose
Maria Elena Gallardo-Martín
Nieves Martínez-Lago
the Galician Group of Research in Digestive Tumors (GITuD)
- Publikationsdatum
- 23.05.2024
- Verlag
- Springer International Publishing
- Erschienen in
-
Targeted Oncology / Ausgabe 4/2024
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X - DOI
- https://doi.org/10.1007/s11523-024-01062-z
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
